Relation of Plasma Lipids to Alzheimer Disease and Vascular Dementia

Overview

Journal Arch Neurol

Specialty Neurology

Date 2004 May 19

PMID 15148148

Citations 161

Authors

Christiane Reitz

Ming-Xin Tang

Jose Luchsinger

Richard Mayeux

Affiliations

Soon will be listed here.

Abstract

Background: The relation between plasma lipid levels and Alzheimer disease (AD) and vascular dementia (VaD), and the impact of drugs to lower lipid levels remains unclear.

Objective: To investigate the relation between plasma lipid levels and the risk of AD and VaD and the impact of drugs to lower lipid levels on this relationship.

Design And Setting: Cross-sectional and prospective community-based cohort studies.

Participants: Random sample of 4316 Medicare recipients, 65 years and older, residing in northern Manhattan, NY.

Main Outcome Measures: Vascular dementia and AD according to standard criteria.

Results: Elevated levels of non-high-density lipoprotein (HDL-C) and low-density lipoprotein cholesterol (LDL-C) and decreased levels of HDL-C were weak risk factors for VaD in either cross-sectional or prospective analyses. Higher levels of total cholesterol were associated with a decreased risk of incident AD after adjustment for demographics, apolipoprotein E genotype, and cardiovascular risk factors. Treatment with drugs to lower lipid levels did not change the disease risk of either disorder.

Conclusions: We found a weak relation between non-HDL-C, LDL-C, and HDL-C levels and the risk of VaD. Lipid levels and the use of agents to lower them do not seem to be associated with the risk of AD.

Citing Articles

The role of statins in dementia or Alzheimer's disease incidence: a systematic review and meta-analysis of cohort studies.

Du Y, Yu Z, Li C, Zhang Y, Xu B Front Pharmacol. 2025; 16:1473796.

PMID: 39963242 PMC: 11830700. DOI: 10.3389/fphar.2025.1473796.

Association of Year-to-Year Lipid Variability With Risk of Cognitive Decline and Dementia in Community-Dwelling Older Adults.

Zhou Z, Moran C, Murray A, Zoungas S, Magnussen C, Chong T Neurology. 2025; 104(4):e210247.

PMID: 39879572 PMC: 11774555. DOI: 10.1212/WNL.0000000000210247.

The Effect of APOE ε4 on Alzheimer's Disease Fluid Biomarkers: A Cross-Sectional Study Based on the COAST.

Zhao B, Zang P, Quan M, Wang Q, Guo D, Jia J CNS Neurosci Ther. 2025; 31(1):e70202.

PMID: 39749650 PMC: 11696244. DOI: 10.1111/cns.70202.

Effects of MIND diet and propolis supplementation on metabolic syndrome indices and cognitive function among patients with metabolic syndrome in Isfahan, Iran, 2024. A rationale and study protocol for randomized controlled trial.

Gholami Z, Maracy M, Paknahad Z Health Sci Rep. 2024; 7(8):e2262.

PMID: 39135701 PMC: 11318029. DOI: 10.1002/hsr2.2262.

Alzheimer's disease and its treatment-yesterday, today, and tomorrow.

Kim A, Al Jerdi S, MacDonald R, Triggle C Front Pharmacol. 2024; 15:1399121.

PMID: 38868666 PMC: 11167451. DOI: 10.3389/fphar.2024.1399121.

References

FRIEDEWALD W, Levy R, Fredrickson D . Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem. 1972; 18(6):499-502. View

Scacchi R, De Bernardini L, Mantuano E, Vilardo T, Donini L, Ruggeri M . DNA polymorphisms of apolipoprotein B and angiotensin I-converting enzyme genes and relationships with lipid levels in Italian patients with vascular dementia or Alzheimer's disease. Dement Geriatr Cogn Disord. 1998; 9(4):186-90. DOI: 10.1159/000017045. View

Paragh G, Balla P, Katona E, Seres I, Egerhazi A, Degrell I . Serum paraoxonase activity changes in patients with Alzheimer's disease and vascular dementia. Eur Arch Psychiatry Clin Neurosci. 2002; 252(2):63-7. DOI: 10.1007/s004060200013. View

Hajjar I, Schumpert J, Hirth V, Wieland D, Eleazer G . The impact of the use of statins on the prevalence of dementia and the progression of cognitive impairment. J Gerontol A Biol Sci Med Sci. 2002; 57(7):M414-8. DOI: 10.1093/gerona/57.7.m414. View

Michikawa M . Cholesterol paradox: is high total or low HDL cholesterol level a risk for Alzheimer's disease?. J Neurosci Res. 2003; 72(2):141-6. DOI: 10.1002/jnr.10585. View

Yoshitake T, Kiyohara Y, Kato I, Ohmura T, Iwamoto H, Nakayama K . Incidence and risk factors of vascular dementia and Alzheimer's disease in a defined elderly Japanese population: the Hisayama Study. Neurology. 1995; 45(6):1161-8. DOI: 10.1212/wnl.45.6.1161. View

Kuriyama M, Hokezu Y, Togo S, Nagata K, Takahashi K, Igakura T . [Serum lipids, lipoproteins and apolipoproteins in patients with senile dementia]. Nihon Ronen Igakkai Zasshi. 1992; 29(7-8):559-64. DOI: 10.3143/geriatrics.29.559. View

Kuusisto J, Koivisto K, Mykkanen L, Helkala E, Vanhanen M, Hanninen T . Association between features of the insulin resistance syndrome and Alzheimer's disease independently of apolipoprotein E4 phenotype: cross sectional population based study. BMJ. 1997; 315(7115):1045-9. PMC: 2127678. DOI: 10.1136/bmj.315.7115.1045. View

Kuriyama M, Takahashi K, Yamano T, Hokezu Y, Togo S, Osame M . Low levels of serum apolipoprotein A I and A II in senile dementia. Jpn J Psychiatry Neurol. 1994; 48(3):589-93. DOI: 10.1111/j.1440-1819.1994.tb03019.x. View

10.

Polidori M, Mecocci P, Frei B . Plasma vitamin C levels are decreased and correlated with brain damage in patients with intracranial hemorrhage or head trauma. Stroke. 2001; 32(4):898-902. DOI: 10.1161/01.str.32.4.898. View

11.

Stern Y, Andrews H, Pittman J, Sano M, Tatemichi T, Lantigua R . Diagnosis of dementia in a heterogeneous population. Development of a neuropsychological paradigm-based diagnosis of dementia and quantified correction for the effects of education. Arch Neurol. 1992; 49(5):453-60. DOI: 10.1001/archneur.1992.00530290035009. View

12.

Hatano S . Experience from a multicentre stroke register: a preliminary report. Bull World Health Organ. 1976; 54(5):541-53. PMC: 2366492. View

13.

Wieringa G, Burlinson S, RAFFERTY J, GOWLAND E, Burns A . Apolipoprotein E genotypes and serum lipid levels in Alzheimer's disease and multi-infarct dementia. Int J Geriatr Psychiatry. 1997; 12(3):359-62. View

14.

Napoli C, Abete P, Corso G, Malorni A, Postiglione A, Ambrosio G . Increased low-density lipoprotein peroxidation in elderly men. Coron Artery Dis. 1997; 8(3-4):129-36. DOI: 10.1097/00019501-199703000-00002. View

15.

Hixson J, Vernier D . Restriction isotyping of human apolipoprotein E by gene amplification and cleavage with HhaI. J Lipid Res. 1990; 31(3):545-8. View

16.

Shapiro S . Bias in the evaluation of low-magnitude associations: an empirical perspective. Am J Epidemiol. 2000; 151(10):939-45. DOI: 10.1093/oxfordjournals.aje.a010135. View

17.

Muldoon M, Barger S, Ryan C, Flory J, Lehoczky J, Matthews K . Effects of lovastatin on cognitive function and psychological well-being. Am J Med. 2000; 108(7):538-46. DOI: 10.1016/s0002-9343(00)00353-3. View

18.

Dietschy J, Turley S . Cholesterol metabolism in the brain. Curr Opin Lipidol. 2001; 12(2):105-12. DOI: 10.1097/00041433-200104000-00003. View

19.

Mayeux R, Ottman R, Maestre G, Ngai C, Tang M, Ginsberg H . Synergistic effects of traumatic head injury and apolipoprotein-epsilon 4 in patients with Alzheimer's disease. Neurology. 1995; 45(3 Pt 1):555-7. DOI: 10.1212/wnl.45.3.555. View

20.

Lopes-Virella M, Stone P, Ellis S, Colwell J . Cholesterol determination in high-density lipoproteins separated by three different methods. Clin Chem. 1977; 23(5):882-4. View